Trial · NCT06937905
Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
NCT06937905, Phase 3, Recruiting, Intergroupe Francophone de Cancerologie Thoracique
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs). Trials, record NCT06937905. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06937905
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
- NCT number
- NCT06937905
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 129 participants, estimated
- Lead sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Conditions
- Neuroendocrine Carcinoma
- Interventions
- Standard of Care Chemotherapy, Tarlatamab
- First posted
- 2025-04-22
- Last updated
- 2026-02-11
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (OS) in patients who received at least one dose of treatment. | About 4 years | Time from date of inclusion to the date of death due to any cause. Time from date of inclusion to the date of death due to any cause. Time from date of inclusion to the date of death due to any cause. |
| Secondary | Safety and tolerability of cemiplimab | About 4 years | Incidence, nature, and severity of treatment-related adverse events/treatment-emergent adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)except CRS and ICANS events graded using ASTCT 2019 |
| Secondary | Objective Response Rate (ORR) | About 4 years | Proportion of patients who have achieved a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) |
| Secondary | Duration of Response (DoR) | About 4 years | Time from the date of the first response (CR or PR) to the earliest date of disease progression |
| Secondary | Disease Control Rate (DCR) | About 4 years | Proportion of patients who have achieved a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) |
| Secondary | Progression-Free Survival (PFS) | About 4 years | Time from randomization to progression or death. |
| Secondary | Overall survival (OS) | About 4 years | Time from date of inclusion to the date of death due to any cause. |
| Secondary | To evaluate the quality of life of patients with questionnaire EORTC Quality of Life Questionnaire - Core C30 (QLQ-C30) | About 4 years | Time to symptom deterioration will be defined as the time from ranodmization until the date of first symptom deterioration. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core Questionnaire C30 (EORTC QLQ-C30) is a 30 item instrument meant to assess some of the different aspects that define the quality of life of cancer patients. Scale : Not at all / A little / Quite a bit / Very much |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06937905
GET https://conductscience.org/api/trials/v1/NCT06937905/registered